article
Beyond the lab: screening
Our inaugural report is an exploration of the remarkable advancements in screening and the field of drug discovery.
List view / Grid view
Exscientia
news
Sanofi and Exscientia establish strategic research collaboration
Sanofi and Exscientia will develop up to 15 novel drug candidates by leveraging the latter's AI discovery and optimisation platform.
news
AI technology to screen existing drugs for use against COVID-19
A collaboration aims to utilise a compound library of 15,000 clinically-ready molecules and screen then against three COVID-19 targets.
article
Discovering and designing drugs with artificial intelligence
The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.
article
Artificial intelligence in the world of drug discovery
Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the field of drug discovery.
news
Exscientia to collaborate with Sanofi for EUR250mil multiple-product development
Exscientia has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.